{"ok":true,"entity":{"id":"biomarin-pharmaceutical","name":"BioMarin Pharmaceutical Inc.","entityType":"company","officialName":"BioMarin Pharmaceutical Inc.","canonicalName":"BioMarin Pharmaceutical Inc.","displayName":"BioMarin Pharmaceutical Inc.","category":"希少遺伝性疾患のバイオ医薬品企業","shortDescription":"BioMarin Pharmaceutical Inc.（NASDAQ: BMRN）は、希少疾患領域のバイオテクノロジー企業で、1997年設立。2026年第2四半期の売上高合計は9億9,000万米ドル（前年同期比20%増）で、2026年4月にAmicus Therapeuticsの買収を完了、同年8月31日にAlesta Therapeutics B.V.の買収も完了した（いずれも2026年10月時点）。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.biomarin.com/","updatedAt":"2026-10-22T11:50:32.298Z","secondaryClusters":[],"alias":["BioMarin","BioMarin Pharmaceutical"],"searchKeywords":["BioMarin","ビオマリン","バイオマリン","希少疾患","VOXZOGO","Amicus買収","BMRN","rare disease biotechnology"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}